PMC:7074432 / 891-3512
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
39 | 12-22 | Chemical | denotes | Nucleoside | MESH:D009705 |
60 | 107-111 | Species | denotes | CoVs | Tax:11118 |
61 | 124-132 | Species | denotes | SARS-CoV | Tax:694009 |
62 | 148-156 | Species | denotes | patients | Tax:9606 |
63 | 263-271 | Species | denotes | SARS-CoV | Tax:694009 |
64 | 416-424 | Species | denotes | SARS-CoV | Tax:694009 |
65 | 587-595 | Species | denotes | patients | Tax:9606 |
66 | 852-861 | Species | denotes | 2019-nCoV | Tax:2697049 |
67 | 30-39 | Chemical | denotes | Ribavirin | MESH:D012254 |
68 | 43-53 | Chemical | denotes | nucleoside | MESH:D009705 |
69 | 175-184 | Chemical | denotes | ribavirin | MESH:D012254 |
70 | 398-407 | Chemical | denotes | ribavirin | MESH:D012254 |
71 | 426-435 | Chemical | denotes | Ribavirin | MESH:D012254 |
72 | 571-580 | Chemical | denotes | ribavirin | MESH:D012254 |
73 | 599-608 | Chemical | denotes | ribavirin | MESH:D012254 |
74 | 760-770 | Chemical | denotes | nucleoside | MESH:D009705 |
75 | 783-794 | Chemical | denotes | favipiravir | MESH:C462182 |
76 | 799-810 | Chemical | denotes | galidesivir | MESH:C517546 |
77 | 467-483 | Disease | denotes | hemolytic anemia | MESH:D000743 |
78 | 485-497 | Disease | denotes | hypocalcemia | MESH:D006996 |
79 | 503-517 | Disease | denotes | hypomagnesemia | MESH:C537153 |
81 | 864-877 | Gene | denotes | Neuraminidase | Gene:4758 |
96 | 889-902 | Gene | denotes | Neuraminidase | Gene:4758 |
97 | 986-994 | Species | denotes | MERS-CoV | Tax:1335626 |
98 | 1043-1051 | Species | denotes | patients | Tax:9606 |
99 | 1085-1093 | Species | denotes | patients | Tax:9606 |
100 | 1107-1122 | Species | denotes | influenza virus | Tax:11309 |
101 | 1243-1251 | Species | denotes | MERS-CoV | Tax:1335626 |
102 | 1312-1320 | Species | denotes | MERS-CoV | Tax:1335626 |
103 | 1373-1382 | Species | denotes | 2019-nCoV | Tax:2697049 |
104 | 949-958 | Species | denotes | influenza | Tax:11309 |
105 | 1061-1072 | Chemical | denotes | oseltamivir | MESH:D053139 |
106 | 1155-1166 | Chemical | denotes | oseltamivir | MESH:D053139 |
107 | 1203-1214 | Chemical | denotes | oseltamivir | MESH:D053139 |
108 | 1297-1308 | Chemical | denotes | oseltamivir | MESH:D053139 |
109 | 1326-1337 | Chemical | denotes | Oseltamivir | MESH:D053139 |
126 | 1716-1723 | Gene | denotes | NSP1–16 | Gene:10045 |
127 | 1564-1572 | Species | denotes | SARS-CoV | Tax:694009 |
128 | 1769-1772 | Species | denotes | CoV | Tax:11118 |
129 | 1896-1899 | Species | denotes | CoV | Tax:11118 |
130 | 2005-2013 | Species | denotes | SARS-CoV | Tax:694009 |
131 | 2585-2594 | Species | denotes | 2019-nCoV | Tax:2697049 |
132 | 2080-2088 | Species | denotes | SARS-CoV | Tax:694009 |
133 | 1812-1821 | Chemical | denotes | lopinavir | MESH:D061466 |
134 | 1849-1859 | Chemical | denotes | saquinavir | MESH:D019258 |
135 | 2019-2022 | Chemical | denotes | pro | MESH:D011392 |
136 | 2099-2108 | Chemical | denotes | lopinavir | MESH:D061466 |
137 | 2158-2161 | Chemical | denotes | HKU | |
138 | 2181-2190 | Chemical | denotes | Ritonavir | MESH:D019438 |
139 | 2211-2220 | Chemical | denotes | lopinavir | MESH:D061466 |
140 | 2425-2444 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
141 | 2504-2525 | Chemical | denotes | lopinavir + ritonavir | MESH:C558899 |
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T143 | 1564-1572 | SP_10 | denotes | SARS-CoV |
T142 | 1648-1656 | MOP:0000780 | denotes | cleaving |
T141 | 1716-1720 | PR:000014815 | denotes | NSP1 |
T140 | 1773-1783 | UBERON:0000104 | denotes | life cycle |
T108 | 878-888 | CHEBI:35222;CHEBI:35222 | denotes | inhibitors |
T107 | 903-913 | CHEBI:35222;CHEBI:35222 | denotes | inhibitors |
T106 | 986-994 | SP_9 | denotes | MERS-CoV |
T105 | 1061-1072 | CHEBI:7798;CHEBI:7798 | denotes | oseltamivir |
T104 | 1107-1116 | NCBITaxon:7719 | denotes | influenza |
T103 | 1117-1122 | NCBITaxon:10239 | denotes | virus |
T102 | 1155-1166 | CHEBI:7798;CHEBI:7798 | denotes | oseltamivir |
T101 | 1203-1214 | CHEBI:7798;CHEBI:7798 | denotes | oseltamivir |
T100 | 1243-1251 | SP_9 | denotes | MERS-CoV |
T99 | 1297-1308 | CHEBI:7798;CHEBI:7798 | denotes | oseltamivir |
T98 | 1312-1320 | SP_9 | denotes | MERS-CoV |
T97 | 1326-1337 | CHEBI:7798;CHEBI:7798 | denotes | Oseltamivir |
T96 | 1373-1382 | SP_7 | denotes | 2019-nCoV |
T80 | 12-22 | CHEBI:33838;CHEBI:33838 | denotes | Nucleoside |
T79 | 30-39 | DG_29 | denotes | Ribavirin |
T78 | 100-106 | NCBITaxon:33208 | denotes | animal |
T77 | 124-132 | SP_10 | denotes | SARS-CoV |
T76 | 175-184 | DG_29;CHEBI:28201;CHEBI:28201 | denotes | ribavirin |
T75 | 196-211 | CHEBI:50858;CHEBI:50858 | denotes | corticosteroids |
T74 | 263-271 | SP_10 | denotes | SARS-CoV |
T73 | 398-407 | CHEBI:28201;DG_29;CHEBI:28201 | denotes | ribavirin |
T72 | 416-424 | SP_10 | denotes | SARS-CoV |
T71 | 426-435 | CHEBI:85129;DG_29;CHEBI:85129 | denotes | Ribavirin |
T70 | 571-580 | DG_29 | denotes | ribavirin |
T69 | 599-608 | DG_29 | denotes | ribavirin |
T68 | 613-627 | CHEBI:50858;CHEBI:50858 | denotes | corticosteroid |
T67 | 667-672 | NCBITaxon:10239 | denotes | viral |
T66 | 760-770 | CHEBI:23447;CHEBI:23447 | denotes | nucleoside |
T65 | 783-794 | CHEBI:119915;CHEBI:119915;DG_17;NCBITaxon:31032 | denotes | favipiravir |
T64 | 799-810 | DG_19;NCBITaxon:9031 | denotes | galidesivir |
T63 | 852-861 | SP_7 | denotes | 2019-nCoV |
T131 | 2181-2190 | DG_30 | denotes | Ritonavir |
T130 | 2211-2220 | DG_23 | denotes | lopinavir |
T139 | 1812-1821 | CHEBI:31781;DG_23;CHEBI:31781 | denotes | lopinavir |
T138 | 1835-1844 | CHEBI:35222;CHEBI:35222 | denotes | inhibitor |
T137 | 1849-1859 | CHEBI:63621;DG_32;CHEBI:63621 | denotes | saquinavir |
T136 | 1883-1892 | CHEBI:35222;CHEBI:35222 | denotes | inhibitor |
T135 | 1981-1991 | CHEBI:35222;CHEBI:35222 | denotes | inhibitors |
T134 | 2005-2013 | SP_10 | denotes | SARS-CoV |
T133 | 2080-2088 | SP_10 | denotes | SARS-CoV |
T132 | 2099-2108 | CHEBI:31781;DG_23;CHEBI:31781 | denotes | lopinavir |
T129 | 2425-2434 | DG_23 | denotes | lopinavir |
T128 | 2435-2444 | DG_30 | denotes | ritonavir |
T127 | 2504-2513 | CHEBI:31781;DG_23;CHEBI:31781 | denotes | lopinavir |
T126 | 2516-2525 | DG_30 | denotes | ritonavir |
T125 | 2585-2594 | SP_7 | denotes | 2019-nCoV |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T1 | 1706-1714 | Body_part | denotes | proteins | http://purl.org/sig/ont/fma/fma67257 |
T2 | 2250-2253 | Body_part | denotes | HIV | http://purl.org/sig/ont/fma/fma278683 |
LitCovid_AGAC
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
p17514s10 | 655-663 | PosReg | denotes | increase |
p17514s12 | 667-677 | MPA | denotes | viral load |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T6 | 124-132 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T7 | 263-271 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T8 | 416-424 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T9 | 467-483 | Disease | denotes | hemolytic anemia | http://purl.obolibrary.org/obo/MONDO_0003664 |
T10 | 477-483 | Disease | denotes | anemia | http://purl.obolibrary.org/obo/MONDO_0002280 |
T11 | 485-497 | Disease | denotes | hypocalcemia | http://purl.obolibrary.org/obo/MONDO_0018543 |
T12 | 503-517 | Disease | denotes | hypomagnesemia | http://purl.obolibrary.org/obo/MONDO_0018100 |
T13 | 949-958 | Disease | denotes | influenza | http://purl.obolibrary.org/obo/MONDO_0005812 |
T14 | 1107-1116 | Disease | denotes | influenza | http://purl.obolibrary.org/obo/MONDO_0005812 |
T15 | 1564-1572 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T16 | 2005-2013 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T17 | 2080-2088 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T2 | 41-42 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T3 | 78-86 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T4 | 100-106 | http://purl.obolibrary.org/obo/NCBITaxon_33208 | denotes | animal |
T5 | 223-224 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T6 | 365-372 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
T7 | 731-732 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T8 | 966-967 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T9 | 1029-1030 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T10 | 1040-1042 | http://purl.obolibrary.org/obo/CLO_0001000 | denotes | 35 |
T11 | 1117-1122 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T12 | 1133-1135 | http://purl.obolibrary.org/obo/CLO_0001407 | denotes | 52 |
T13 | 1322-1324 | http://purl.obolibrary.org/obo/CLO_0053733 | denotes | 11 |
T14 | 1578-1580 | http://purl.obolibrary.org/obo/CLO_0052906 | denotes | CL |
T15 | 2259-2260 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T16 | 2382-2383 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T2 | 12-22 | Chemical | denotes | Nucleoside | http://purl.obolibrary.org/obo/CHEBI_33838 |
T3 | 41-53 | Chemical | denotes | a nucleoside | http://purl.obolibrary.org/obo/CHEBI_33838 |
T4 | 68-77 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T5 | 175-184 | Chemical | denotes | ribavirin | http://purl.obolibrary.org/obo/CHEBI_63580 |
T6 | 196-211 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
T7 | 298-303 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T8 | 398-407 | Chemical | denotes | ribavirin | http://purl.obolibrary.org/obo/CHEBI_63580 |
T9 | 571-580 | Chemical | denotes | ribavirin | http://purl.obolibrary.org/obo/CHEBI_63580 |
T10 | 599-608 | Chemical | denotes | ribavirin | http://purl.obolibrary.org/obo/CHEBI_63580 |
T11 | 613-627 | Chemical | denotes | corticosteroid | http://purl.obolibrary.org/obo/CHEBI_50858 |
T12 | 760-770 | Chemical | denotes | nucleoside | http://purl.obolibrary.org/obo/CHEBI_33838 |
T13 | 783-794 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
T14 | 864-888 | Chemical | denotes | Neuraminidase inhibitors | http://purl.obolibrary.org/obo/CHEBI_52425 |
T15 | 878-888 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T16 | 889-913 | Chemical | denotes | Neuraminidase inhibitors | http://purl.obolibrary.org/obo/CHEBI_52425 |
T17 | 903-913 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T18 | 1061-1072 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T19 | 1155-1166 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T20 | 1203-1214 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T21 | 1297-1308 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T22 | 1326-1337 | Chemical | denotes | Oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T23 | 1475-1480 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T24 | 1511-1520 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
T25 | 1706-1714 | Chemical | denotes | proteins | http://purl.obolibrary.org/obo/CHEBI_36080 |
T26 | 1791-1810 | Chemical | denotes | protease inhibitors | http://purl.obolibrary.org/obo/CHEBI_37670|http://purl.obolibrary.org/obo/CHEBI_60258 |
T28 | 1800-1810 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T29 | 1812-1821 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T30 | 1835-1844 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
T31 | 1849-1859 | Chemical | denotes | saquinavir | http://purl.obolibrary.org/obo/CHEBI_63621 |
T32 | 1883-1892 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
T33 | 1981-1991 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T34 | 2099-2108 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T35 | 2211-2220 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T36 | 2425-2444 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T37 | 2425-2434 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T38 | 2435-2444 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T39 | 2504-2513 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T40 | 2516-2525 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T41 | 2545-2563 | Chemical | denotes | protease inhibitor | http://purl.obolibrary.org/obo/CHEBI_37670|http://purl.obolibrary.org/obo/CHEBI_60258 |
T43 | 2554-2563 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T5 | 0-10 | Sentence | denotes | Antivirals |
T6 | 12-29 | Sentence | denotes | Nucleoside analog |
T7 | 30-272 | Sentence | denotes | Ribavirin, a nucleoside analog, shows antiviral activity against some animal CoVs, and in the SARS-CoV epidemic, many patients were treated with ribavirin along with corticosteroids and became a standard regimen for the treatment of SARS-CoV. |
T8 | 273-348 | Sentence | denotes | However, lack of control group hindered the estimation of true effect size. |
T9 | 349-425 | Sentence | denotes | Again, in vitro testing did not show efficacy of ribavirin against SARS-CoV. |
T10 | 426-519 | Sentence | denotes | Ribavirin is known for its side effects (hemolytic anemia, hypocalcemia, and hypomagnesemia). |
T11 | 520-581 | Sentence | denotes | Many subsequent studies questioned the efficacy of ribavirin. |
T12 | 582-702 | Sentence | denotes | Many patients on ribavirin and corticosteroid combination even showed an increase in viral load following the treatment. |
T13 | 703-862 | Sentence | denotes | Thus, its use declined over a period.[8] Other important nucleoside analogs are favipiravir and galidesivir, but these are not evaluated till now in 2019-nCoV. |
T14 | 864-888 | Sentence | denotes | Neuraminidase inhibitors |
T15 | 889-1081 | Sentence | denotes | Neuraminidase inhibitors are indicated in the management of influenza.[9] In a study on possible MERS-CoV cases in Paris from 2013 to 2016, a total of 35 patients received oseltamivir (37.6%). |
T16 | 1082-1500 | Sentence | denotes | In patients positive for influenza virus (n = 25), 52% (n = 13) received oseltamivir and it was concluded that empirical oseltamivir can be started in suspected MERS-CoV cases.[10] Many other studies also evaluated oseltamivir in MERS-CoV.[11] Oseltamivir was also used in the management of 2019-nCoV; however, definite evidence of efficacy is inconclusive because of lack of suitable control group in the studies.[12] |
T17 | 1502-1520 | Sentence | denotes | Protease inhibitor |
T18 | 1521-1784 | Sentence | denotes | There are two types of protease present in SARS-CoV, the CL-like protease and the papain-like protease, which is important for cleaving the polyproteins and releasing the nonstructural proteins (NSP1–16), which carry out important functions in the CoV life cycle. |
T19 | 1785-2621 | Sentence | denotes | Among protease inhibitors, lopinavir was the most inhibitor and saquinavir was the least powerful inhibitor of CoV protease.[13] In molecular dynamic studies, flap closing was observed when these inhibitors bound to the SARS-CoV 3CL (pro).[14] Hong Kong University researchers demonstrated anti-SARS-CoV action of lopinavir at concentration of 4 μg/ml in vitro against the HKU-39849 isolate.[15] Ritonavir boosting along with lopinavir is used in the management of HIV.[16] A clinical study at the same Hong Kong University suggests that even after adjustment for LDH level (possible confounder), a significant association was seen between lopinavir/ritonavir use and better outcome.[15] As per the current guidelines, lopinavir + ritonavir is the recommended protease inhibitor for the treatment of 2019-nCoV (weak recommendation).[17] |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T2 | 467-483 | Phenotype | denotes | hemolytic anemia | http://purl.obolibrary.org/obo/HP_0001878 |
T3 | 485-497 | Phenotype | denotes | hypocalcemia | http://purl.obolibrary.org/obo/HP_0002901 |
T4 | 503-517 | Phenotype | denotes | hypomagnesemia | http://purl.obolibrary.org/obo/HP_0002917 |
2_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
32201439-17597972-47219406 | 741-742 | 17597972 | denotes | 8 |
32201439-30012113-47219407 | 1259-1261 | 30012113 | denotes | 10 |
32201439-30882305-47219408 | 1322-1324 | 30882305 | denotes | 11 |
32201439-31986264-47219409 | 1497-1499 | 31986264 | denotes | 12 |
32201439-18706430-47219410 | 2025-2027 | 18706430 | denotes | 14 |
32201439-14985565-47219411 | 2177-2179 | 14985565 | denotes | 15 |
32201439-16827606-47219412 | 2255-2257 | 16827606 | denotes | 16 |
32201439-14985565-47219413 | 2469-2471 | 14985565 | denotes | 15 |
32201439-32029004-47219414 | 2618-2620 | 32029004 | denotes | 17 |
T83959 | 741-742 | 17597972 | denotes | 8 |
T19064 | 1259-1261 | 30012113 | denotes | 10 |
T33497 | 1322-1324 | 30882305 | denotes | 11 |
T42850 | 1497-1499 | 31986264 | denotes | 12 |
T5394 | 2025-2027 | 18706430 | denotes | 14 |
T51142 | 2177-2179 | 14985565 | denotes | 15 |
T94741 | 2255-2257 | 16827606 | denotes | 16 |
T99431 | 2469-2471 | 14985565 | denotes | 15 |
T46519 | 2618-2620 | 32029004 | denotes | 17 |